OH Pharma
Products › Mitochondria and cellular energy › Elamipretide 10 mg
Elamipretide 10 mg OH PharmaElamipretide 10 mg OH Pharma – back of vial

Mitochondria and cellular energy · File 14

Elamipretide 10 mg

Analysis in progress

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Peptides targeting mitochondrial function.

Calculate a dose →

Description

Tetrapeptide that binds to cardiolipin, a lipid of the inner mitochondrial membrane.

Studied benefits

  • Improved muscle strength that supported a US accelerated approval for Barth syndrome, in patients weighing at least 30 kg.
  • Action on cardiolipin, a component of mitochondrial membranes.

Results reported in published research; they guarantee no effect and are not an indication for use.

🔬 What the research says
  • Approved in the United States to improve muscle strength in people with Barth syndrome.
⚠️ Warnings and reported side effects
  • Very common injection-site reactions: redness, pain, induration, itching, hives.
  • Rise in eosinophils (white blood cells) with prolonged use.
  • Serious hypersensitivity reactions reported; adjustment required in severe kidney impairment.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate of analysis coming soon

This product's lot is awaiting its laboratory results. The certificate will be published on this page as soon as it is received. Every new lot is sent for analysis before being published here.

Sources

  1. Forzinity monograph (Drugs.com)
  2. HealthDay — FDA approval (2025)
  3. Health Canada — advisory on unauthorized injectable peptides (April 2026)

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products